No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ENOV240816C50000
- 0.50
- -0.19-27.54%
15min DelayTrading Jul 23 09:37 ET
0.50High0.50Low
0.50Open0.69Pre Close1 Volume99 Open Interest50.00Strike Price50.00Turnover65.26%IV9.97%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.3496Delta0.0475Gamma27.01Leverage Ratio-0.0611Theta0.0097Rho9.44Eff Leverage0.0442Vega
Intraday
- 5D
- Daily
News
Investors in Enovis (NYSE:ENOV) Have Unfortunately Lost 41% Over the Last Three Years
Market Cool On Enovis Corporation's (NYSE:ENOV) Revenues
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
Enovis Expands Shoulder Implant Offerings
Express News | Enovis Releases AltiVate Reverse Glenoid System
Comments
The company's use of debt is seen as risky due to its EBIT loss and the liabilities it has. The balance sheet is not considered strong, but it could improve over time. The stock is considered quite risky.
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt 1
Needham analysts predict Enovis's new products, orthopedic market strength, and the Lima acquisition will exceed 2024 consensus. They also foresee Paragon 28 returning to roughly 20% revenue growth in 2024 due to new bunion-focused products, supply chain enhancements, and sales force growth.
Enovis CEO Matt Trerotola praised Shirley, Vogt, and Ross for their roles in the company's growth. He highlighted Shirley's influence on Enovis's transformation to a medtech firm, Vogt's contribution to the U.S. surgical business growth, and Ross's work in ensuring sustained growth in the P&R segment.
Enovis' falling revenue and absent profits might have led to a drop in share price. Viewing the total shareholder return and recent share price rise, the company may suggest investment potential if it shows sustainable long term growth.
Enovis's rise in liabilities and recent EBIT loss spark concerns about its debt use and future profitability. With a negative free cash flow of US$106m over the past year, the company's financial risk is evident. Balance sheet situation calls for caution due to dubious circumstances.
Read more